Business Context and Reporting Period
Company: Coherus Biosciences, Inc. (formerly Coherus Oncology, Inc.)
Filing Type: Form 8-K (Current Report)
Date: September 13, 2024
Subject: Regulation FD Disclosure regarding supply chain updates for the UDENYCA product line.
Key Financial Metrics and Operational Status
This filing does not report specific revenue, profit, cash flow, or debt figures for a completed period. Key operational and financial data points include:
- Expense Guidance: Combined R&D and SG&A expenses for 2024 are reaffirmed at $250 million to $265 million.
- Stock-Based Compensation: Approximately $40 million of the expense guidance is attributed to stock-based compensation.
- Supply Chain Investment: Over $30 million invested since 2021 to diversify production ($25 million for drug substance, $6 million for drug product fill).
- Cost Reduction Target: Projected reduction in UDENYCA production costs by approximately one-third from current levels.
Material Changes and Supply Chain Interruption
The Company reported a temporary supply interruption for UDENYCA (a biosimilar to Neulasta) due to capacity constraints at its U.S.-based third-party Contract Manufacturing Organization (CMO) for final labeling and packaging.
- Scope: Delays are limited to labeling and final packaging; active pharmaceutical ingredient and drug product manufacturing are unaffected.
- Timeline: Channel supply is projected to be substantially depleted by mid-October 2024.
- Resumption: Manufacturing is expected to resume in mid-October 2024, with product availability resuming by early November 2024.
- Strategic Response: The Company has engaged a second final packaging and labeling CMO. Commercial supply from this new facility is expected to commence in Q1 2025, which will more than double packaging capacity to over 1 million units.
Guidance, Outlook, and Risks
Management Commentary:
- The Company aims to offset short-term revenue impacts from the supply interruption with sales later in the fourth quarter of 2024.
- Expedited shipping measures are in place to minimize disruption upon supply resumption.
- Further updates will be provided during the third-quarter 2024 earnings announcement.
- Reliance on third-party CMOs for critical supply chain steps.
- Risks associated with scaling up supply capacity and complying with FDA regulatory requirements.
- Potential for manufacturing delays and competitive pressures.
Investor Verification Checklist
- Verify the actual duration of the supply interruption and the precise date of product availability resumption in early November 2024.
- Monitor the Q3 2024 earnings report for quantified revenue impacts resulting from the mid-October inventory depletion.
- Confirm the qualification timeline and commercial readiness of the second packaging CMO for Q1 2025.
- Review the 10-Q filed on August 8, 2024, for detailed risk factors regarding third-party manufacturing dependencies.